Alexion, AstraZeneca's Rare Disease's Biologics License Application (BLA) for efzimfotase alfa has been accepted and granted Priority Review by the US Food and Drug Administration (FDA) for the ...

Alexion, AstraZeneca Rare Disease's Klygefa (gefurulimab) has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP), recommending its ...

EU Medicines Agency Panel Backs Indication Extension for AstraZeneca, Daiichi Sankyo's Breast Cancer Drug MT 09:05am AstraZeneca, Daiichi celebrate another recommended approval of Enhertu AN 08:38am ...

Alexion, AstraZeneca's Rare Disease's Biologics License Application (BLA) for efzimfotase alfa has been accepted and granted Priority Review by the US ...

Alexion, AstraZeneca Rare Disease's Klygefa (gefurulimab) has been recommended for approval in the European Union (EU) as an add-on to standard ...

AstraZeneca (AZN) said Friday the US Food and Drug Administration granted priority review to its Alexion unit's biologics license application for efzimfotase alfa to treat patient ...

An experimental drug from AstraZeneca succeeded in a late-stage trial in an autoimmune condition called generalized myasthenia gravis, positioning the company to grow a business it inherited when ...

Lights, camera, Alexion! Fresh off earning FDA approval for its drug Ultomiris to treat certain adults with neuromyelitis optica spectrum disorder (NMOSD), AstraZeneca’s rare disease unit has put out ...

A year after debuting the “Rare Connections” series with a short film about patients’ experiences with neuromyelitis optica spectrum disorder (NMOSD), AstraZeneca’s rare disease unit is turning the ...